Next Phase Newsletter

An investor group based out of New York, USA with financial backing from China in looking at US-based opportunities that they believe will translate well to the Chinese market. These opportunities do not need to already have traction in China since the firm hopes to be a Chinese partner to help them access and succeed in these markets in addition to being an investor. The firm expects to make 20-50 investments this year and is prioritizing investments in the $10-50 million USD range, but is also willing to look at earlier stage opportunities.

The firm is interested in medical devices. Specifically, medical devices related to senior care, health planning, data collection, data analysis and management, 24/7 patient monitoring systems, and devices that can help facilitate conversations between patients and caregivers. Companies they’ve worked with and still have interest for include: laser treatment devices for arthritis, devices for rehabilitation, and devices for surgery. The firm is generally less interested in pure healthcare IT. For device companies, the firm prefers that they already have FDA approval, but are willing to look at companies who are close to completing FDA pivotal trials as well.

The firm prefers companies that are ideally already revenue generating, but they are also willing to look at companies that are near revenue generation. The firm wants to work with companies who are interested in accessing the Chinese market and are willing to form a joint venture with the firm in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A diversified business based in Japan has opened US corporate venture offices in Massachussets and California. The corporate venture fund has an evergreen structure looking to allocate between $1-$3 million per deal initially and up to $5 million over the life of the investment. The firm seeks to invest in approximately 2-4 companies over the next 12 months and are open to investing in companies across the globe.

Sectors of interest include: pharmaceuticals, medical device and digital health. Therapeutic and product areas of interest include: Pain, critical care, cardiovascular disease, musculoskeletal disease, kidney disease, patient monitoring technologies, bioprocessing technologies, digital therapeutics. The firm is open to all stages of investment, with a general preference toward companies with at least some early clinical data.

The firm invests in private companies and is willing to work with all types of management teams including incomplete teams. They generally request at least an observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Yuanta Asia Investment is an investment firm based in Taiwan. The firm is the subsidiary of Yuanta Securities, a Taiwanese securities house with approximately USD 6.8 billion AUM and subsidiary of Yuanta Financial Holdings. The firm engages in M&A, underwriting, as well as direct investments. The firm is interested in the life sciences and will target new investments from a new USD 100 million fund. The firm can sometimes leverage different funds to invest. The fund’s target investment size is USD 3-5 million per company in average, USD 5-15M for pre-IPO round and USD 1-1.5 million for early stage companies. Capital allocation per company will not exceed 10% of the fund. The firm seeks companies in Asia-Pacific, including the US and Japan. The firm is actively seeking new investment opportunities.

In the life sciences, the firm is interested in therapeutics, medical devices, and diagnostics. For therapeutics, the firm will consider a broad range of modalities including small molecules and biologics with an emphasis on immunotherapy or other breakthrough technology in CNS related disease. The firm is opportunistic in terms of indications. For companies in Asia, the firm is agnostic to the phase of development. For overseas deals, the firm is currently looking for preclinical to phase 2 assets. The firm prefers candidates with in-human data and are conducting clinical trials in the US, while this is not a requirement.

For devices, the firm considers minimally invasive class III devices in the cardiovascular and cancer space that have prototype and have obtained proof-of concept. For diagnostics, the firm is interested in genomics and big data analytics. Recently there is an interest in the cosmetics and supplements area, and the firm is seeking acquisition opportunities to commercialize products through distribution channels within its network. The firm is also looking for the target in pre-IPO round of placement in NASDAQ or other market.

The firm only invests in private companies and looks to hold less than 15 percent of total shares of the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A healthcare asset management institution based China manages more than 20 healthcare equity investment funds and is currently investing from its US$50 million fund focusing on early stage opportunities from North America. The firm prefers to follow a syndicate in Angel and Pre-Series A rounds. Typical investment ranges from US$0.5 to 1 million.

The firm is interested in medical devices and diagnostic technologies that have large market potential in China. The firm prefers products in pre-clinical and clinical development stage. The firm is agnostic to indication areas.

The firm is looking for experienced management teams with strong sector knowledge. Leveraging its network and portfolio companies, the firm can assist with finding local registration and distribution partners and may request regional rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A healthcare-focused venture capital and growth equity firm currently manages ~$750 million, providing $15-$30 million of equity capital per company over the life of the investment. The firm is primarily looking for companies throughout North America and Europe.

The firm is currently interested in companies in areas of medical technology, biopharmaceuticals, diagnostics, medical devices, digital health, and veterinary medicine. Significant emphasis is placed on the clinical utility and health economics of potential investments. The firm focuses on later-stage opportunities whereby the company has a clear path through regulatory approval, reimbursement, and commercialization. The firm is generally open in terms of indications.

The firm looks for management teams that are very willing to work alongside them, and most always looks to take a board seat. The firm is open to investing in both public and privately held companies, is open to a variety of deal structures, and can consider equity investments or buy-out opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Chinese healthcare company focused on researching, developing, and promoting innovative medicine is looking to invest in or acquire assets that they consider interesting and unique. The firm has no set number of allocations for this upcoming year and is willing to look at opportunities from all over the globe. The firm does not require a China angle to be present when investing.

The firm is interested in therapeutics and also in devices (specifically devices related to imaging). In regard to therapeutics assets, the firm is willing to look at pre-clinical assets as well as assets that are at phase II and up. For pre-clinical assets, they require that the assets be first-in class to be considered for investment or acquisition. For phase II and up assets, the firm will analyze assets based on commercial capabilities. The majority of the firm’s current portfolio lies in the oncology, pain, and cardiovascular fields, but they are agnostic and are willing to look at other assets as well.

Companies interested in acquisition must have certain commercialization capabilities already such as a sales team and have a value of at least $200M USD. The firm also makes direct minority investments and will consider making a direct investment if they believe the company has the capability to develop the asset of interest on their own.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global pharmaceutical company headquartered in Japan is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. The firm is currently looking for partnering and in-licensing opportunities across the globe.
The firm is currently looking for innovative therapeutics targeting the following priority areas: thrombosis & thrombolysis, pain management, cardiovascular disease, CNS, and rare diseases. Other interest areas include metabolic diseases, oncology, organ fibrosis and NAFLD/NASH, neurology, immunology, and mitochondrial disease. The firm is open to biologics or molecular targets, with an increased interest in new platform technologies. The following areas are currently out of focus: diabetes, hypertension, dyslipidemia, psychiatric diseases, and immunodeficiency.

The firm partners with privately held life science companies with experienced management teams and innovative technologies in the abovementioned areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com